Spots Global Cancer Trial Database for Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer

Official Title: Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification

Study ID: NCT01674556

Conditions

Pancreatic Adenocarcinoma

Interventions

Gemzar

Study Description

Brief Summary: The investigators primary aim is to increase chemotherapeutic drug uptake in inoperable tumours The specific sub-objectives of the studies are: * To quantify tumour sizes and relate it to the patient survival over time, dependent of treatment method. * To evaluate and compare the toxic effects and safety of gemcitabine in combination with US contrast agent under sonication with gemcitabine alone. * Develop and validate new ultrasound perfusion algorithms based on burst- replenishment for diagnosis and monitoring of therapy. * To quantify gemcitabine and its main metabolites in plasma and in circulating mononuclear cells before, during and after pancreatic sonication, and to quantify the concentration of intracellular endogenous nucleotides in circulating mononuclear cells at the same time points. * To assess plasma and tissue concentrations of gemcitabine, its main metabolites and endogenous nucleotides in those patients where surgical resection can be performed on standard clinical indications.

Detailed Description: The primary outcome is monitor for toxicity effect for the combination therapy.